The second half of the earnings season is well under way, but a host of key companies remain set to report and give investors insight into what may be next for the stock market and the economy. More than 70 S & P 500 names are slated to report this week, including Disney and Caterpillar . Pharmaceutical giant Eli Lilly is also set to post earnings. The earnings season overall has been solid. Year-over-year S & P 500 profit growth in the second quarter is on track to exceed 11%, and nearly 78% of companies have thus far beaten estimates, according to FactSet. To be sure, corporations that don’t meet the high bar set by analysts and investors continue to be punished. Case in point, Amazon: The e-commerce behemoth issued lackluster guidance for its fiscal third quarter, sending shares tumbling . Take a look at CNBC Pro’s breakdown of what’s expected from this week’s key reports. All times are Eastern. Tuesday Uber Technologies is set to report earnings before the bell. A call with management is set for 8 a.m. Last quarter: UBER posted Q1 revenue that beat analyst expectations . This quarter: The ride-hailing giant is expected to report a 70% year-over-year increase in earnings, LSEG data shows. What CNBC is watching: Uber heads into its second-quarter report with some regulatory momentum, after a California court ruled that app-based workers could be classified as independent contractors. Investors will now look for clues on whether consumer spending on ride-hailing and delivery service is pulling back. “The stock appear to have priced in softening ride frequency trends in addition to continued concern around Autonomous Vehicle (AV) competition, creating an undemanding setup for Uber heading into the print,” wrote Deutsche Bank analyst Benjamin Black. What history shows: Uber has beaten earnings expectations in six of the last seven quarters, according to data from Bespoke Investment Group. Caterpillar is set to report premarket earnings, followed by a conference call with leadership at 8:30 a.m. Last quarter: CAT reported earnings and revenue that beat analyst expectations, but shares slid 7%. This quarter: Analysts expect earnings and revenue to have remained little changed from the year-earlier period, according to LSEG. What CNBC is watching: Investors will look through Caterpillar’s report for clues on the state of the global economy, given the company’s worldwide presence. Over the past three months, shares have fallen 4.3%. What history shows: The industrial giant’s earnings have beaten expectations for five straight quarters, Bespoke data shows. To be sure, shares have fallen on three of those reporting days. Wednesday Walt Disney is set to report earnings before the open. A conference call with analysts and investors is set for 8:30 a.m. Last quarter: DIS fell 10% on soft guidance that offset a strong showing from its streaming business. This quarter: The theme park operator and movie studio is expected to report a 15% earnings increase, according to LSEG. What CNBC is watching: Disney’s parks business will be in focus for investors. “The stock is now trying to price in incremental Parks pressures,” wrote Wells Fargo analyst Steven Cahall. “We think in a downside scenario, domestic attendance goes ex-growth but the bigger hits are per [capita] growth being more heavily negative, and hotel RevPAR.” What history shows: Disney earnings beat analyst expectations 78% of the time, according to Bespoke. But the stock is typically flat on earnings days. Thursday Eli Lilly is set to report earnings ahead of the opening bell, followed by a call at 10 a.m. Last quarter: LLY posted an earnings beat and hiked its full-year outlook on strong sales of Zepbound . This quarter: The pharma giant’s earnings grew by nearly 30% from the year-earlier period, according to LSEG. What CNBC is watching: All eyes will be on Eli Lilly’s blockbuster weight loss drug Zepbound. Last week, analysts at JPMorgan wrote: “Longer-term, we continue to see significant upside for Mounjaro/Zepbound with 2024 sales of $16.5bn (+$1.3bn) growing to $27bn in 2025 (+$3.5bn) and $36.5bn in 2026 (+$5.8bn). Additionally, there remain several important catalysts for LLY’s incretin franchise over the next 12-18 months including tirzepatide health outcomes data.” What history shows: Eli Lilly has topped earnings estimates for four straight quarters. But the shares average a 0.2% decline on earnings days.
Discussion about this post